← All trials
NCT03394196
N/AInterventional
Trials without FDA-defined phases, including trials of devices or behavioral interventions.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jul 4, 2018
- Primary completion
- Jan 31, 2021
- Completion date
- Jul 31, 2021
- First posted
- —
- Last posted
- —
- Enrollment
- 150
- Arms / groups
- 3 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of WashingtonLead sponsor
- Janssen Pharmaceutica NVCollaborator
- MerckCollaborator
- National Institute of Allergy and Infectious Diseases (NIAID)Collaborator
- University of WashingtonReponsible party - principal investigator
- University of WashingtonOverall official - principal investigator
- Centre de Sante de Ziguinchor, Casamance, SenegalCollaborator
- CHU Fann DakarCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.